Phase I/II, open label study of sequential Taxotere (docetaxel) and Gleevec (imatinib mesylate) in hormone refractory prostate cancer.

Next Previous
Trial Profile

Phase I/II, open label study of sequential Taxotere (docetaxel) and Gleevec (imatinib mesylate) in hormone refractory prostate cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2011

At a glance

  • Drugs Docetaxel; Imatinib
  • Indications Prostate cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 11 Jan 2011 Actual end date changed from Apr 2010 to May 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top